What does PHARMAPOINT do?

PHARMAPOINT is a pharmacy in Maasmechelen. Public Limited, started on 15 September 1988, 1 establishment.

What is the address of PHARMAPOINT?

The registered office of PHARMAPOINT is located at Thomasboslaan(M) 98, 3630 Maasmechelen.

Is PHARMAPOINT still active?

Yes. According to the CBE (30 October 2026) PHARMAPOINT is active, legal situation “Normale toestand”, started on 15 September 1988.

Is PHARMAPOINT registered on Peppol?

Yes, PHARMAPOINT is registered on the Peppol network with ID 0208:0435330555.

What is the enterprise number of PHARMAPOINT?

The enterprise number of PHARMAPOINT is BE0435330555.

When was PHARMAPOINT founded?

PHARMAPOINT was founded on 15 September 1988.

Who are the directors of PHARMAPOINT?

According to the 2025 annual accounts, the directors of PHARMAPOINT are: Antoon Medaer, Medipharma BV.

Is PHARMAPOINT a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 15 September 1988; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did PHARMAPOINT make in 2025?

PHARMAPOINT posted a profit after taxes of € 85,567 in financial year 2025.

What is the revenue of PHARMAPOINT?

As a small company, PHARMAPOINT is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 210,598.

How much does an employee at PHARMAPOINT earn?

The average wage cost per full-time employee at PHARMAPOINT was € 54,600 in 2024: staff costs of € 109,159 for 2 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does PHARMAPOINT have?

According to the 2025 annual accounts, PHARMAPOINT has 0.9 full-time equivalents (FTE).

PHARMAPOINT (Public Limited) - Maasmechelen

Dossier PHARMAPOINT, printed on 30 October 2026 from databakkes.be/en/0435330555/pharmapoint. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

PHARMAPOINT from Maasmechelen, company number BE0435330555, closed financial year 2025 with a result of € 85,567 after tax. For that financial year PHARMAPOINT recorded a gross margin of € 210,598 and equity of € 106,312. Compared with financial year 2024, the result moved from € 32,956 to € 85,567. Profitable, and profit is growing. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 12, 2026.

What it is worth Growing

€ 106,312

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 85,567

▲ 160% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 10,857

▼ 26% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 85,500 paid out

100 % of the profit went to the shareholders, mostly to MEDIPHARMA (100 % of the shares). That is where the money ends up.

People and assets in 2025

Full-time equivalents

0.9

▼ 1.1 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 30,493

▼ 72% vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Debts at end 2025

Bank debt ≈ 6 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 565,886

▼ 14% vs 2024

€ 79,249 is repaid this year. At this pace the long-term loan is gone in ≈ 6 years.

Owed to suppliers

€ 214,745

▼ 18% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 2,482

▼ 42% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 323,836 Gross margin 2022: € 323,836 First fiscal year in the series	€ 282,514 Gross margin 2023: € 282,514 ▼ 13% vs 2022 (€ 323,836) Unfavourable step	€ 234,044 Gross margin 2024: € 234,044 ▼ 17% vs 2023 (€ 282,514) Unfavourable step	€ 210,598 Gross margin 2025: € 210,598 ▼ 10% vs 2024 (€ 234,044) Unfavourable step	▼ 10%
Profit after taxes	€ 177,879 Profit after taxes 2022: € 177,879 First fiscal year in the series	€ 118,360 Profit after taxes 2023: € 118,360 ▼ 33% vs 2022 (€ 177,879) Unfavourable step	€ 32,956 Profit after taxes 2024: € 32,956 ▼ 72% vs 2023 (€ 118,360) Unfavourable step	€ 85,567 Profit after taxes 2025: € 85,567 ▲ 160% vs 2024 (€ 32,956) Favourable step	▲ 160%
Equity	€ 105,829 Equity 2022: € 105,829 First fiscal year in the series	€ 106,189 Equity 2023: € 106,189 Unchanged (€ 105,829) Favourable step	€ 106,245 Equity 2024: € 106,245 Unchanged (€ 106,189) Favourable step	€ 106,312 Equity 2025: € 106,312 Unchanged (€ 106,245) Favourable step
Total debts	€ 1,074,243 Total debts 2022: € 1,074,243 First fiscal year in the series	€ 988,983 Total debts 2023: € 988,983 ▼ 8% vs 2022 (€ 1,074,243) Favourable step	€ 962,760 Total debts 2024: € 962,760 ▼ 3% vs 2023 (€ 988,983) Favourable step	€ 917,356 Total debts 2025: € 917,356 ▼ 5% vs 2024 (€ 962,760) Favourable step	▼ 5%
Cash	€ 11,758 Cash 2022: € 11,758 First fiscal year in the series	€ 902 Cash 2023: € 902 ▼ 92% vs 2022 (€ 11,758) Unfavourable step	€ 14,665 Cash 2024: € 14,665 ▲ € 13,763 vs 2023 (€ 902) Favourable step	€ 10,857 Cash 2025: € 10,857 ▼ 26% vs 2024 (€ 14,665) Unfavourable step	▼ 26%
Land & buildings	€ 453,517 Land & buildings 2022: € 453,517 First fiscal year in the series	€ 417,411 Land & buildings 2023: € 417,411 ▼ 8% vs 2022 (€ 453,517) Unchanged	€ 381,305 Land & buildings 2024: € 381,305 ▼ 9% vs 2023 (€ 417,411) Unchanged	€ 345,199 Land & buildings 2025: € 345,199 ▼ 9% vs 2024 (€ 381,305) Unchanged	▼ 9%
Retained profit	€ 43,829 Retained profit 2022: € 43,829 First fiscal year in the series	€ 44,189 Retained profit 2023: € 44,189 ▲ 1% vs 2022 (€ 43,829) Favourable step	€ 44,245 Retained profit 2024: € 44,245 Unchanged (€ 44,189) Favourable step	€ 44,312 Retained profit 2025: € 44,312 Unchanged (€ 44,245) Favourable step
Dividend	€ 175,000 Dividend 2022: € 175,000 First fiscal year in the series	€ 118,000 Dividend 2023: € 118,000 ▼ 33% vs 2022 (€ 175,000) Unchanged	€ 32,900 Dividend 2024: € 32,900 ▼ 72% vs 2023 (€ 118,000) Unchanged	€ 85,500 Dividend 2025: € 85,500 ▲ 160% vs 2024 (€ 32,900) Unchanged	▲ 160%
Bank debt	€ 721,995 Bank debt 2022: € 721,995 First fiscal year in the series	€ 694,904 Bank debt 2023: € 694,904 ▼ 4% vs 2022 (€ 721,995) Favourable step	€ 655,395 Bank debt 2024: € 655,395 ▼ 6% vs 2023 (€ 694,904) Favourable step	€ 565,886 Bank debt 2025: € 565,886 ▼ 14% vs 2024 (€ 655,395) Favourable step	▼ 14%
Balance sheet total	€ 1,180,072 Balance sheet total 2022: € 1,180,072 First fiscal year in the series	€ 1,095,172 Balance sheet total 2023: € 1,095,172 ▼ 7% vs 2022 (€ 1,180,072) Unchanged	€ 1,069,005 Balance sheet total 2024: € 1,069,005 ▼ 2% vs 2023 (€ 1,095,172) Unchanged	€ 1,023,668 Balance sheet total 2025: € 1,023,668 ▼ 4% vs 2024 (€ 1,069,005) Unchanged	▼ 4%
Employees (FTE)	2.8 Employees (FTE) 2022: 2.8 First fiscal year in the series	1.7 Employees (FTE) 2023: 1.7 ▼ 1.1 vs 2022 (2.8) Unchanged	2 Employees (FTE) 2024: 2 ▲ 0.3 vs 2023 (1.7) Unchanged	0.9 Employees (FTE) 2025: 0.9 ▼ 1.1 vs 2024 (2) Unchanged	▼ 1.1

Key figures of PHARMAPOINT, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PHARMAPOINT?

What happened at PHARMAPOINT in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2027 Antoon Medaer stepped down as director. NBB
2027 Medipharma BV stepped down as director. NBB
Jun 12, 2026 New annual accounts for financial year 2025: profit of € 85,567 (▲ 160% vs 2024). Source: NBB ↗
2021 Antoon Medaer became a director. NBB
2021 Medipharma BV became a director. NBB
Oct 4, 1988 New establishment in Maasmechelen. KBO
Sep 15, 1988 Start of the company according to the CBE. KBO

In short

From € 177,879 profit in 2022 to € 85,567 profit in 2025.

Paid € 3,009 in corporate taxes since 2022.

Best year ever: 2022, with € 177,879 profit.

On average € 117,000 of value added per employee in 2024.

Original PDFs at the National Bank ↗

Management

MEDIPHARMA 100%

The stake of MEDIPHARMA comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

PHARMAPOINT

The shares are held by MEDIPHARMA (100%).

Directors

According to the 2025 annual accounts

Antoon Medaer

Bestuurder

since 2021 · until 2027

Medipharma BV

Gedelegeerd bestuurder · represented by Ann Hendrix

since 2021 · until 2027

Shareholders

MEDIPHARMA

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Thomasboslaan(M) 98

3630 Maasmechelen

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0435.330.555

VAT number

BE 0435.330.555

Registered office

Thomasboslaan(M) 98, 3630 Maasmechelen

Names & denominations

PHARMAPOINT

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

15 September 1988

Peppol

Active · Active since 24 Nov 2023

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

PHARMAPOINT

Financials

What happened to PHARMAPOINT?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Details

Frequently asked questions